NCT06882447View on ClinicalTrials.gov

A Study of QL1706 Combined with Nine HPV Vaccine As First-line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Cervical Cancer Stage IVB
Interventions
DRUG

Trial drug: QL1706, HPV 9-valent vaccine

QL1706: Dose: 5 mg/kg ; intravenous infusion (ivgtt), administered on day 1 of each cycle and once every 3 weeks (21 days).

All Listed Sponsors
lead

Northern Jiangsu People's Hospital

OTHER